Mechanistic target of rapamycin complex 1 and complex 2 (mTORC1 and mTORC2)

Mechanistic target of rapamycin complex 1 and complex 2 (mTORC1 and mTORC2) are two distinct multiprotein kinase complexes assembled around the serine/threonine kinase mTOR. Both complexes function as central regulators of cell growth, metabolism, and survival by integrating signals from nutrients, energy status, growth factors, and stress. mTORC1 is primarily responsible for promoting anabolic processes such as protein synthesis, lipid synthesis, and inhibiting autophagy, whereas mTORC2 regulates cell survival and cytoskeletal organization through phosphorylation of AGC family kinases including AKT, SGK1, and PKCs. Dysregulation of these complexes is implicated in cancer, metabolic, cardiovascular, and neurodegenerative diseases. Rapamycin-class drugs selectively inhibit mTORC1, while dual mTORC1/mTORC2 inhibitors target both complexes. Safety concerns with mTOR-targeting therapies include metabolic complications and immunosuppression.

Other names

mTOR complex 1mTOR complex 2Mammalian target of rapamycin complex 1Mammalian target of rapamycin complex 2mTORC1 (for complex 1)mTORC2 (for complex 2)Rapamycin-sensitive complex (for mTORC1)Rapamycin-insensitive complex (for mTORC2)

Allosteric inhibition of mTORC1 (Rapamycin and analogs bind FKBP12, inhibiting mTORC1) ATP-competitive kinase inhibition (inhibiting both mTORC1 and mTORC2)